PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
HLB Pharma posted record annual revenue in 2025 and stayed profitable, but operating margin remains around 1%, while a rights offering to fund its new Hyangnam plant is underway.
2025 consolidated revenue rose about 50% year over year to KRW 205.6 billion, but operating margin was only 0.5%.
First-half 2026 revenue reached KRW 127.9 billion, a record for the period, with balanced growth across prescription drugs and consumer healthcare.
The company is pursuing a KRW 120 billion rights offering for its new Hyangnam plant and R&D, though a lower issue price has reduced the actual amount to be raised.
Operating and net income both slipped back into small losses in Q2 2026, showing continued quarter-to-quarter earnings volatility.
Meeting the R&D-to-revenue ratio (7%) required for innovative pharmaceutical company certification under revised drug-pricing rules remains a medium-term task.
HLB Pharma is a mid-sized pharmaceutical company operating ethical prescription drugs (ETC), consumer healthcare (health supplements), and contract manufacturing (CMO), with production bases at its Namyangju headquarters plant and Hyangnam plant.
In the ETC segment, key products including Rosuduo, Tinza, and Citrocin drove double-digit growth, with first-half 2026 ETC sales up 12% year over year to KRW 69.0 billion. Retail prescription performance grew 15% year over year, far outpacing the overall market growth rate of 5%.
The consumer healthcare business posted strong results across online, home-shopping, and offline channels, with first-half sales surging 152% year over year to KRW 12.0 billion. In April 2025 the company acquired pharmaceutical distributor Shinhwa Advance, pursuing vertical integration that extends into distribution.
It has also been converting outsourced production to in-house manufacturing to improve profitability, with plans to eventually serve as a production hub for HLB Group's new drug pipeline.
On the R&D side, the company is expanding investment in its long-acting injectable platform (SMEB), including a diabetes/obesity pipeline (HLBP-038) and an anticoagulant candidate (HLBP-024).
Competitively, Korea's generic and mid-sized pharmaceutical market features intense rivalry among numerous small and mid-cap players, and HLB Pharma differentiates itself through in-house production and a newly acquired distribution affiliate to strengthen cost and supply-chain competitiveness.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | — | — | — |
| 2025Q3 | ₩60.6B | ₩34,119,430 | 0.1% |
| 2025Q4 | ₩63.4B | ₩800M | 1.3% |
| 2026Q1 | ₩65.7B | ₩1B | 1.6% |
| 2026Q2 | ₩62.3B | -₩30,961,995 | −0.0% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩107.5B | -₩6.4B | -₩11.8B | −6.0% | −13.7% | 65.5% |
| 2023 | ₩136B | -₩19.5B | -₩19.4B | −14.4% | −22.0% | 60.3% |
| 2024 | ₩137.1B | ₩1.5B | ₩2B | 1.1% | 1.7% | 35.7% |
| 2025 | ₩205.6B | ₩1.1B | ₩4.6B | 0.5% | 3.7% | 36.4% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04
HLB Pharma's annual revenue expanded steadily from KRW 107.5 billion in 2022 to KRW 135.9 billion in 2023, KRW 137.1 billion in 2024, and KRW 205.6 billion in 2025.
Profitability, however, has been far more volatile: operating losses widened from KRW 6.4 billion (OPM -6.0%) in 2022 to KRW 19.5 billion (OPM -14.4%) in 2023, before the company swung to an operating profit of KRW 1.5 billion (OPM 1.1%) in 2024.
In 2025, even as revenue jumped roughly 50% year over year, operating profit came in at only KRW 1.1 billion with margin falling to 0.5%, showing that top-line growth and margin improvement have not yet moved fully in lockstep.
Net income attributable to owners moved from losses of KRW 11.8 billion in 2022 and KRW 19.4 billion in 2023 to profits of KRW 2.0 billion in 2024 and KRW 4.6 billion in 2025.
On a quarterly basis, Q3 2025 revenue was KRW 60.6 billion with a marginal operating profit of KRW 0.03 billion and a net loss of KRW 0.2 billion, before Q4 improved to revenue of KRW 63.4 billion, operating profit of KRW 0.8 billion, and net profit of KRW 2.3 billion.
Q1 2026 continued this trend with revenue of KRW 65.7 billion, operating profit of KRW 1.0 billion, and net profit of KRW 0.7 billion, but Q2 2026 revenue slipped slightly to KRW 62.3 billion while operating and net income both turned negative, at roughly -KRW 0.03 billion and -KRW 0.06 billion respectively.
Over the trailing four quarters (Q3 2025 through Q2 2026), net income attributable to owners totaled about KRW 2.8 billion, indicating the company is profitable on an annual basis but still experiences swings between quarters.
This pattern likely reflects a combination of the in-house production conversion, changes in revenue mix from the newly consolidated distribution subsidiary, and seasonal factors.
Korea's pharmaceutical industry is characterized by intense competition among numerous small and mid-sized generic-focused companies, with the overall retail prescription market reportedly growing at around 5% per year.
HLB Pharma's retail prescription performance outpaced this by more than 10 percentage points, growing faster than the market average. The health supplement market continues to expand, led by online and home-shopping channels, and HLB Pharma has posted balanced gains across these channels as well.
On the policy front, South Korea's Ministry of Health and Welfare approved reforms to the national health insurance drug-pricing system in March 2026, tightening pricing criteria; companies must now obtain innovative pharmaceutical company certification to retain the prior 60% preferential pricing rate.
Certification requires an R&D-to-revenue ratio of at least 7%, whereas HLB Pharma's three-year average (2023-2025) stood at only 3.37%, implying a significant step-up in investment is needed.
This represents a structural shift that could widen the competitiveness gap between companies with sufficient R&D capacity and smaller peers that lack it.
Separately, as an HLB Group affiliate, HLB Pharma's results are not directly tied to the group's new drug pipeline commercialization progress (such as rivoceranib), but sentiment toward group-affiliated stocks can still be influenced by such developments.
The company plans to expand annual production capacity from 300 million tablets to at least 700 million tablets through construction of its new Hyangnam plant, converting a substantial portion of outsourced production to in-house manufacturing.
To fund this, it decided in May 2026 on a KRW 120 billion rights offering, allocating KRW 55 billion to the new plant, KRW 25 billion to R&D, KRW 25 billion to working capital, and KRW 15 billion to debt repayment.
However, following a subsequent share price decline, the first issue price set in early August 2026 was lowered to KRW 5,650, shrinking the expected proceeds to roughly KRW 60.9 billion.
The registration statement took effect on August 14, 2026, with subsequent amendment filings continuing to adjust the final fundraising size and schedule.
R&D spending is set to be concentrated on the long-acting injectable platform (SMEB)-based diabetes/obesity and anticoagulant pipelines, along with in-house bioequivalence testing.
This is not merely pipeline expansion but also a strategic investment aimed at meeting innovative pharmaceutical company certification requirements to defend preferential drug pricing.
The company has set 2028 as its target for obtaining this certification, which will require roughly doubling its current R&D-to-revenue ratio to the required 7%.
Once the new plant is fully operational, it is expected to improve cost competitiveness while also potentially serving as a production hub for HLB Group's new drug pipeline.
HLB Pharma has emerged from years of losses and shown a recent earnings recovery trend, though quarterly results continue to alternate between small profits and small losses.
The stock trades at a premium to net asset value, and the valuation multiple the market assigns relative to its earnings base sits near the upper end of its historical trading range, a pattern typical of companies in the early stages of a turnaround.
The company currently pays no dividend, suggesting a policy that prioritizes funding growth investments such as the new plant and R&D over shareholder returns via dividends.
The ongoing rights offering could dilute per-share metrics once new shares are issued, so caution is warranted in assessing per-share value until the final issue size and price are confirmed.
When interpreting valuation, it is reasonable to weigh both the directional trend in annual earnings (the swing from losses to profit and the subsequent pace of earnings recovery) and the timing of completion of the ongoing capital-raising event.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04
2025 revenue grew roughly 50% year over year, and first-half 2026 revenue hit a record, extending the growth trend. Diversification into prescription drugs, consumer healthcare, and distribution (via Shinhwa Advance) is reducing reliance on any single segment.
Retail prescription performance has significantly outpaced the market average growth rate, underpinning product competitiveness.
Once the new Hyangnam plant is completed, production capacity will expand from 300 million to at least 700 million tablets, reducing reliance on outsourced manufacturing. The shift to in-house production is expected to help lower manufacturing costs and improve supply stability.
Vertical integration through the distribution subsidiary acquisition is also a potential factor for improving cost and distribution margin structure.
Investment is expanding in the long-acting injectable platform (SMEB)-based diabetes/obesity and anticoagulant pipelines. A significant portion of the rights offering proceeds is earmarked for R&D, which could accelerate pipeline progress.
Successful innovative pharmaceutical company certification would also bring a tangible benefit in preserving preferential drug pricing.
Operating margin was only 0.5% in 2025, and the company slipped back into an operating loss in Q2 2026. Despite revenue growth, profitability improvement has repeatedly failed to keep pace. High quarter-to-quarter earnings volatility means it will take time to confirm a stable earnings trajectory.
The planned KRW 120 billion rights offering involves a substantial new share issuance that could reduce existing shareholders' ownership percentage. While a lower-than-planned issue price has reduced the amount raised, it also risks slowing the pace of achieving the intended funding purposes (the new plant and R&D). Uncertainty remains until the final issue price and new share listing date are set.
Failure to obtain innovative pharmaceutical company certification under the revised drug-pricing system could result in a lower preferential pricing rate. The company's three-year average R&D ratio of 3.37% is less than half the required 7% threshold, necessitating a substantial increase in investment. Expanded R&D spending could add near-term pressure on profitability.
The issue price of the ongoing rights offering could be adjusted further depending on market conditions, directly affecting the amount raised and the execution plan for new-plant and R&D investment.
If forfeited shares occur, additional uncertainty exists related to the general public offering process and underwriting terms. The extent of equity dilution is difficult to gauge until the final issue price and listing schedule are confirmed.
Following the March 2026 reform of the national health insurance drug-pricing system, the level of preferential pricing will depend on whether innovative pharmaceutical company certification is obtained.
Failure to meet the certification requirement (a 7% R&D-to-revenue ratio) could result in a lower pricing rate than before. Given its generic-drug-centered business structure, the company has relatively high sensitivity to changes in government drug-pricing policy.
As an HLB Group affiliate, group-level new drug approval and regulatory issues (such as FDA review of rivoceranib) can affect sentiment across affiliated stocks. In the past, when the group's new drug received a Complete Response Letter (CRL) from the FDA, affiliate share prices fell sharply in tandem. Share price volatility unrelated to HLB Pharma's own results can therefore arise from group-level events.
Watch for confirmation of the final issue price and new share listing schedule for the ongoing rights offering, and the actual amount to be raised.
The FDA priority review decision for parent company HLB's (028300) cholangiocarcinoma drug candidate rivoceranib-partner asset is scheduled, which could affect sentiment across group-affiliated stocks.
The Q3 2026 earnings release will show whether growth in the ETC and consumer healthcare segments and the operating margin trend continue.
Check whether the target completion timeline for the new Hyangnam plant is met and track progress on the in-house production conversion rate.
Monitor whether the R&D-to-revenue ratio (7%) required for innovative pharmaceutical company certification is being met, along with the status of the application and review process.
HLB Pharma continues to expand its top line through balanced growth in prescription drugs and consumer healthcare, along with vertical integration via its distribution subsidiary acquisition, and has maintained annual profitability since 2024.
However, operating margin remains low at around 1%, and the company slipped back into a small loss in Q2 2026, showing that quarter-to-quarter earnings volatility has not been resolved.
A rights offering to fund the new Hyangnam plant and expanded R&D is underway, but the amount to be raised has shrunk from the original plan due to a lower issue price, with final terms still unconfirmed.
Meeting the innovative pharmaceutical company certification requirement under the revised drug-pricing system also remains a challenge given current R&D investment levels, requiring further expansion.
As a group affiliate, shifts in sentiment toward HLB Group stocks tied to new drug approval events also warrant attention. Overall, the company sits at a juncture where positive revenue growth and diversification coexist with challenges around low margins, equity dilution, and regulatory certification requirements.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.